N-Acetyl-L-Tyrosine
NALT · NAT · N-acetyltyrosine · Ac-Tyr-OH
Last updated
At a glance
Overview
NALT has built a reputation as the "focus-under-pressure" amino acid — the supplement people reach for before a fasted morning cardio session, a deep-cut posing practice, an exam, or a long-haul travel day. The mechanism is clean and well-documented: tyrosine is the rate-limiting substrate for dopamine and norepinephrine synthesis, and under acute stressors that drain those pools — cold, hypoxia, sleep deprivation, sustained cognitive load — substrate loading measurably preserves working memory, mood, and psychomotor accuracy.
The honest catch is that NALT and L-tyrosine are not interchangeable. The acetylated form was developed for parenteral nutrition because plain L-tyrosine is barely water-soluble. Orally, a meaningful fraction of NALT is excreted intact in urine before it ever becomes usable tyrosine, and the typical 300–500 mg cap is well below the gram-scale doses that produced signal in the military stress literature. The community-experienced position is that plain L-tyrosine at 1–2 g, pulse-dosed before a real stressor, outperforms boutique NALT capsules in nearly every scenario.
"A significant fraction of N-acetyl-L-tyrosine is excreted unchanged in urine during intravenous infusion, confirming incomplete hydrolysis and limiting its efficiency as a tyrosine precursor." — Magnusson et al., Metabolism (1989)
The sections below cover the mechanism in detail, evidence-based dosing for both NALT and L-tyrosine, the specific protocols where substrate loading actually moves the needle (acute stress, fat-loss phases, cold exposure, stimulant-recovery days), stacking with caffeine and theanine, the contraindications that matter (MAOIs, levodopa, melanoma history), and why pulse dosing beats chronic daily use.
How N-Acetyl-L-Tyrosine works
Catecholamine Precursor Loading#
NALT is a prodrug. The acetylated molecule itself does nothing at central receptors — it must first be deacetylated by renal and hepatic acylases to liberate free L-tyrosine, the actual bioactive species. Free tyrosine then crosses the blood–brain barrier via the LAT1 large neutral amino acid transporter, where it competes with tryptophan, phenylalanine, and the branched-chain aminos for entry. This is the reason fasted or low-protein-window administration is the published convention: a high-protein meal floods the transporter and brain tyrosine uptake collapses.
Once intraneuronal, tyrosine is the substrate for tyrosine hydroxylase (TH) — the rate-limiting enzyme of catecholamine synthesis. TH converts tyrosine → L-DOPA → dopamine → norepinephrine → epinephrine. Under resting conditions TH is substrate-saturated and additional tyrosine produces nothing useful. The mechanism only "switches on" when catecholaminergic firing is elevated and the neurons are pulling substrate faster than baseline diet supplies it.
Stress-Conditional Activation#
This is the part the marketing copy usually skips: tyrosine loading is not a general-purpose cognitive enhancer. It only produces measurable cognitive benefit when the catecholamine system is being actively depleted by an acute stressor — cold, hypoxia, sleep deprivation, sustained multitasking load, or combined physical/cognitive demand. The military literature is unambiguous on this point.
"Tyrosine administration preserved cognitive performance and working memory during cold exposure, compared to placebo, particularly in the latter stages when core temperature decreased the most." — O'Brien, C. et al. Physiology & Behavior, 2007
"Tyrosine-treated subjects performed better on several cognitive tests and mood assessments when subjected to cold and hypoxia stress compared to placebo-treated controls." — Banderet, L.E. & Lieberman, H.R. Brain Research Bulletin, 1989
The practical translation for physique-focused users: NALT shines pre-fasted cardio in a cold gym, pre-AM training during a deep cut, pre-sauna/ice-bath block, or during sleep-restricted contest-prep weeks. It does very little for a well-fed, well-rested user doing a standard hypertrophy session.
Incomplete Deacetylation and Renal Loss#
The mechanistic Achilles heel of NALT specifically (versus plain L-tyrosine) is that the acetyl group is not efficiently removed in mammals. A meaningful fraction of administered NALT is filtered and excreted intact before it can be hydrolyzed to free tyrosine.
"At a dose of 0.5 mmol NAT/kg/day, labeled tyrosine pool specific activities increased in liver, kidney, and plasma, but the plasma tyrosine concentration remained at fasting levels... 8.3% of the infused [14C]NAT was excreted unchanged in urine." — Im, A.H., Meyer, P.D., Stegink, L.D. Pediatric Research, 1985
Magnusson and colleagues, infusing NAT intravenously in humans, observed the same pattern of partial hydrolysis and substantial urinary loss of intact molecule, and concluded the compound is an inefficient tyrosine precursor relative to free tyrosine or tyrosine dipeptides. The practical consequence is that the 300–500 mg NALT caps sold as nootropics deliver, after the deacetylation penalty and the renal loss, a fraction of what equimolar plain L-tyrosine would deliver to the catecholamine pool.
Why Plain L-Tyrosine Usually Wins#
The peptide-bound form (glycyl-L-tyrosine) used in clinical parenteral nutrition outperforms NALT head-to-head for raising plasma tyrosine, and free oral L-tyrosine outperforms NALT for the same endpoint at the doses people actually administer.
"N-acetyl-L-tyrosine proved less efficient than glycyl-L-tyrosine for maintaining plasma tyrosine and supporting growth, primarily because of partial deacetylation and renal excretion of intact molecule." — Neuhäuser, M. et al. American Journal of Clinical Nutrition, 1985
NALT's one genuine mechanistic advantage is solubility — it dissolves cleanly into a pre-workout drink where plain L-tyrosine clumps and tastes chalky. That is a formulation advantage, not a pharmacological one, and it does not survive the math when gram-scale dosing is required.
Downstream Endpoints#
When the mechanism does fire — acute stressor, fasted administration, adequate dose — the catecholamine pool replenishment produces the endpoints documented in the literature:
- Working memory and psychomotor accuracy preservation under cold and hypoxic load.
- Mood and subjective-effort buffering during combined physical/cognitive stress.
- Sustained attention during sleep-deprived task performance.
- Substrate support for dopaminergic stacks (phenylpiracetam) and overnight catecholamine recovery in stimulant users.
What the mechanism does not do, despite frequent claims: build muscle, burn fat directly, alter hormonal axes, modulate sleep architecture, or produce chronic cognitive enhancement in unstressed subjects. NALT is a narrow tool for a specific neurochemical situation — and respected as such, it earns a place in the acute-stress and cut-phase stack.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 300–500 mg | As needed | Documented entry-level range |
| Mid | 500–1000 mg | As needed | Most commonly studied range |
| High | 1000–2000 mg | As needed | Pulse-dosed 45–60 min before a cognitive or thermal stressor, on a fasted or low-protein stomach. Competing LNAAs in a high-protein meal blunt brain uptake. Daily chronic use produces tachyphylaxis within 1–2 weeks — rest days are standard. |
Cycle length & outcomes
Documented cycle
4 weeks
Plateau after
2 wks
Cycle Structure#
NALT is not cycled the way hormonal compounds are cycled. There is no suppression, no receptor downregulation requiring washout, and no PCT. What there is is tachyphylaxis — the acute catecholaminergic lift blunts within roughly 1–2 weeks of daily chronic use, and the protocol that preserves effect is pulse dosing before specific stressors, not blanket daily administration.
The mechanism logic backs this up. Tyrosine hydroxylase is saturated under unstressed baseline conditions, so substrate loading on a calm Tuesday afternoon produces nothing measurable. The published effect sizes come from administration before a documented stressor — cold, hypoxia, sleep deprivation, or sustained multitasking load:
"Tyrosine-treated subjects performed better on several cognitive tests and mood assessments when subjected to cold and hypoxia stress compared to placebo-treated controls." — Banderet & Lieberman, Brain Research Bulletin (1989)
"Tyrosine administration preserved cognitive performance and working memory during cold exposure, compared to placebo, particularly in the latter stages when core temperature decreased the most." — O'Brien et al., Physiology & Behavior (2007)
Dose Ladder by Use Case#
Doses below are expressed as L-tyrosine equivalents. NALT delivers less tyrosine per milligram than the plain amino acid because partial deacetylation and renal excretion eat into the yield — Im, Meyer & Stegink documented 8.3% of an IV NAT dose excreted intact in urine, rising at higher doses:
"At a dose of 0.5 mmol NAT/kg/day, labeled tyrosine pool specific activities increased in liver, kidney, and plasma, but the plasma tyrosine concentration remained at fasting levels... 8.3% of the infused [14C]NAT was excreted unchanged in urine." — Im, Meyer & Stegink, Pediatric Research (1985)
To approximate a given L-tyrosine dose with oral NALT, scale up roughly 1.3–1.5×. In practice, gram-scale plain L-tyrosine is the more economical move; NALT is used where solubility in a mixed pre-workout drink matters.
| Use Case | Cycle Pattern | Acute Dose (L-tyrosine) | Acute Dose (NALT equiv) | Timing |
|---|---|---|---|---|
| Pre-task focus / interview / exam | Single pulse, as-needed | 500–1000mg | 750–1500mg | 45–60 min prior, fasted |
| Pre-fasted cardio on a deep cut | Training days only, 4–8 weeks | 500–1000mg | 750–1500mg | 30–45 min prior, with caffeine |
| Cold-exposure / ice bath / cold gym session | Pulse before exposure | 100–150 mg/kg | 130–200 mg/kg | 60 min prior |
| Sleep-deprived workday | As-needed, max 2–3×/week | 1–2g | 1.5–3g | AM, fasted |
| Stimulant-day catecholamine support | Evening of stimulant days | 500mg–1g | 750mg–1.5g | Evening, away from stimulant by 6+ hours |
| Combined acute stressors (cold + altitude + load) | Single pulse | 100–150 mg/kg | 130–200 mg/kg | 60 min prior |
Onset and Duration#
Free tyrosine peaks in plasma roughly 1–2 hours after an oral dose, with subjective and measurable cognitive effects landing in the 45–90 minute window and decaying over 4–6 hours. The acute pre-stressor window is therefore narrow — dosing 3 hours before a task is too early, and dosing 15 minutes before is too late.
NALT adds a deacetylation step that pushes the curve slightly later and lower than plain L-tyrosine. The community-standard pre-task timing of "60 minutes before" applies cleanly to L-tyrosine; NALT users tilt closer to 75–90 minutes.
Loading, Tapering, and Pulse Logic#
- No loading phase. Catecholamine substrate effects are acute, not cumulative. The first dose works as well as the hundredth — provided the hundredth isn't following ten days of consecutive daily dosing.
- No taper. Discontinuation produces no rebound, no withdrawal, no HPA disruption.
- Pulse dosing is the protocol. Standard community structure is acute dosing 2–4 times per week before identified stressors, with rest days between. Blanket daily chronic use is the most common community pitfall and the fastest route to "NALT stopped working."
- Maximum continuous run: roughly 2 weeks before effect blunts noticeably. Reset by stopping for 7–10 days.
Stack Cadence#
The classic caffeine + L-theanine + tyrosine stack runs on training days during a cut and rests on off-days. A workable 8-week cut structure:
| Weeks | Pattern |
|---|---|
| 1–2 | Caffeine 150mg + theanine 200mg + L-tyrosine 1g, pre-AM cardio, 4×/week |
| 3 | Off — preserve sensitivity |
| 4–5 | Same stack, 4×/week, training days only |
| 6 | Off |
| 7–8 | Same stack, ramped to 5×/week if needed for contest week |
For users running phenylpiracetam or modafinil, NALT/L-tyrosine slots in as substrate support on dosing days, not as a daily companion.
Bloodwork and Monitoring#
None required at supplement doses. The compound has no hormonal, hepatic, or renal monitoring footprint in healthy adults. Two narrow exceptions:
- Chronic gram-scale users (anyone running 2g+ daily for months on end, against the pulse-dosing convention) — an annual TSH and free T4 check is a reasonable optimization move, since tyrosine is the thyroid hormone precursor. No solid clinical signal of dysfunction exists at supplement doses; this is precautionary.
- High-volume NALT users specifically carry slightly higher solute load on the kidneys due to the unconverted-and-excreted fraction. Not clinically meaningful in healthy subjects, but a reason gram-scale dosing favors plain L-tyrosine over NALT on grounds of efficiency:
"A significant fraction of N-acetyl-L-tyrosine is excreted unchanged in urine during intravenous infusion, confirming incomplete hydrolysis and limiting its efficiency as a tyrosine precursor." — Magnusson et al., Metabolism (1989)
Common Cycle Mistakes#
- Daily chronic dosing. Effect fades inside 2 weeks. Pulse instead.
- Co-administration with a high-protein meal. Competing LNAAs (tryptophan, leucine, valine, isoleucine, methionine, phenylalanine) saturate LAT1 and blunt brain tyrosine entry. Fasted or low-protein-window dosing is the published convention.
- Under-dosing NALT and expecting Banderet/Lieberman effect sizes. A 350mg cap is mechanistically below the threshold that produced signal in the cold/hypoxia literature. Either dose at gram scale or use plain L-tyrosine.
- Stacking with prescription stimulants in the same time window. Tyrosine and amphetamine compete for the same transporter; concurrent dosing blunts the stimulant. Separate by 4+ hours.
- Dosing on calm days. Without a stressor, tyrosine hydroxylase is already saturated and additional substrate produces nothing. NALT is a stress-conditional tool, not a daily smart drug.
Run cleanly, pulsed before real cognitive or thermal load, dosed at adequate scale and on an empty stomach, this compound delivers a narrow but reproducible cognitive lift exactly where the literature predicts it should.
Risks & mistakes
Common (most users)#
NALT is one of the better-tolerated entries in the nootropic stack. Most reported effects are mild, dose-dependent, and resolve quickly:
- Mild GI upset or nausea — most often at gram-scale single doses on an empty stomach. Mitigation: drop the dose to 500 mg, or pair with a small low-protein snack (a piece of fruit, plain rice cake) that won't load the LNAA transporter with competing amino acids.
- Jitteriness or over-stimulation — almost always when stacked with high-dose caffeine or other catecholaminergic agents. Reduce caffeine first, not the tyrosine. 100–150 mg caffeine + 1 g L-tyrosine is a more sustainable pairing than 300 mg caffeine + 500 mg NALT.
- Headache — typically transient, dehydration-linked, and resolves with water. If it recurs on every dose, the catecholaminergic load is too high for that individual; halve the dose.
- Sleep disruption — predictable if dosed late. Confine administration to pre-noon or, at the latest, six hours before intended sleep onset.
- Tachyphylaxis / fading effect — the single most common complaint on r/Nootropics. Daily use blunts the acute focus signal within 1–2 weeks. Mitigation is structural, not pharmacological: pulse-dose on demand, with rest days the default.
Uncommon (dose-dependent or individual)#
- Transient blood pressure elevation at very high acute doses (gram-scale, fasted, stacked with caffeine). Mechanistically expected from norepinephrine substrate-loading. Users with borderline hypertension or those running AAS with cardiovascular load should check resting BP before scaling past 1 g per dose.
- Anxiety or emotional flattening on chronic daily use — anecdotally reported after several weeks of uninterrupted dosing. Resolves on washout. Pulse dosing prevents it.
- Blunted stimulant absorption when co-administered with prescription amphetamine, methylphenidate, or modafinil. Tyrosine and these stimulants compete for the LAT1 transporter. Separate doses by at least 90 minutes — or use tyrosine the morning after a stimulant day for pool replenishment, not concurrently.
- Renal solute load — a meaningful fraction of NALT is excreted intact in urine rather than deacetylated to free tyrosine:
"At a dose of 0.5 mmol NAT/kg/day, labeled tyrosine pool specific activities increased in liver, kidney, and plasma, but the plasma tyrosine concentration remained at fasting levels... 8.3% of the infused [14C]NAT was excreted unchanged in urine." — Im AH, Meyer PD, Stegink LD, Pediatric Research (1985)
Clinically irrelevant in healthy kidneys at supplement doses, but worth noting for users running multiple compounds with renal clearance.
- Theoretical thyroid drift on chronic gram-scale use — tyrosine is the thyroid hormone precursor. No solid clinical signal exists at supplement doses, but annual TSH/free T4 monitoring is a reasonable optimization-minded move for anyone running 2+ g daily for months.
Rare but serious#
- Hypertensive episode when NALT is combined with MAO inhibitors. This is a mechanistic certainty, not a theoretical concern — catecholamine and tyramine accumulation under MAO inhibition is the classic "tyramine reaction" pathway. Warning signs: severe occipital headache, palpitations, sudden BP spike. Discontinue immediately.
- Migraine triggering in susceptible individuals — tyrosine and tyramine-pathway metabolites can precipitate vascular headache in known migraineurs. Discontinue if a clear pattern emerges.
- Inefficient conversion at high doses — relevant for users trying to chase the published military-literature effect sizes by pushing NALT into multi-gram territory:
"A significant fraction of N-acetyl-L-tyrosine is excreted unchanged in urine during intravenous infusion, confirming incomplete hydrolysis and limiting its efficiency as a tyrosine precursor." — Magnusson I, Ekman L, Wångdahl M, Wahren J, Metabolism (1989)
The practical implication: scaling NALT past 2 g per dose returns diminishing brain tyrosine and rising urinary loss. Switch to plain L-tyrosine rather than chasing the curve.
Hard contraindications#
- MAOIs (phenelzine, tranylcypromine, antidepressant-dose selegiline, moclobemide): tyrosine loading under MAO inhibition risks hypertensive crisis. Do not combine.
- Levodopa therapy (Parkinson's disease): LNAA competition at LAT1 reduces L-DOPA brain entry and blunts levodopa efficacy. Do not combine.
- Untreated hyperthyroidism: avoid until euthyroid — tyrosine is the substrate for T3/T4 synthesis.
- Active or historical melanoma, or extensive dysplastic nevi: tyrosine is the melanin precursor. Clinical relevance at supplement doses is unproven, but the cautious default is to skip it entirely.
- Pregnancy and lactation: safety data are absent. Avoid.
- Pheochromocytoma or any catecholamine-secreting tumor: absolute contraindication on mechanism alone.
Gender-specific and PCT notes#
NALT has no hormonal mechanism. No sex-specific dose adjustment, no virilization risk, no impact on the HPTA, and no PCT requirement. It stacks cleanly alongside AAS, SARMs, peptides, and hair protocols without pharmacological interaction. The only sex-specific caveat is the absence of pregnancy and lactation data — default to avoidance in that population. For users running stimulants (prescription ADHD medications, modafinil, clenbuterol on a cut), the relevant interaction is transporter competition, not endocrine: separate dosing windows, and reserve NALT for either pre-stressor loading or next-day pool replenishment rather than concurrent administration.
FAQ — N-Acetyl-L-Tyrosine
Research & citations
5 studies cited on this page.
Conclusion
N-acetyl-l-tyrosine (NALT) delivers fast, pulse-dosed catecholamine support under stress — but the literature and community practice agree: plain L-tyrosine is the more efficient substrate for raising brain dopamine and norepinephrine, especially for cognitive focus during acute stressors.
Key takeaways:
- Typical NALT dose: 500–1500 mg orally, 45–60 min pre-stressor; higher doses (up to 2 g) may be required to approach published L-tyrosine effect sizes
- Pulse, not daily — protocols avoid chronic use to prevent rapid tachyphylaxis and emotional blunting
- Most effective as a pre-task or pre-stress nootropic: cold exposure, sleep deprivation, deep cuts, or high-cognitive-load scenarios
- Stacks cleanly with caffeine and L-theanine for a focus-supporting pre-workout or workday blend
- Solubility is NALT's only real advantage over plain L-tyrosine — cost-per-effect and conversion favor the parent amino acid
- Contraindicated with MAOIs, levodopa, uncontrolled hyperthyroidism, or melanoma history
For anyone designing a nootropic or fat-loss stack aimed at cognitive resilience under stress, L-tyrosine (or NALT for mixability) remains a validated, flexible tool — just pulse it with intent and dose high enough for effect.